Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity
Touyun Biotech Group Limited (HK:1332) announced a strategic cooperation agreement to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028. This comes amid unusual market activity, with a significant increase in share price and trading volume. The company confirmed its operations remain normal. The latest analyst rating for the stock is a Hold with a price target of HK$0.50. The current market cap is HK$1.08B, with an average trading volume of 1,589,265.
China Touyun Tech Group ( (HK:1332) ) has provided an announcement.
Touyun Biotech Group Limited announced an unusual increase in its share price and trading volume, with no known reasons for these movements. The company confirmed that its operations remain normal and disclosed a strategic cooperation agreement with a sales consortium to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028, indicating potential growth opportunities.
The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.
More about China Touyun Tech Group
Touyun Biotech Group Limited, incorporated in Bermuda, operates in the biotechnology industry. The company, along with its subsidiaries, focuses on producing and marketing Chlamydomonas reinhardtii and related products, with a strategic market focus on expanding its reach through collaborations.
Average Trading Volume: 1,589,265
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.08B
